網上行寬頻新標準, 將速度全面提升, 提供1G 至10G的選擇, 為今日、未來作好準備。Netvigator redefines broadband by massively upgrading its speed and taking it to higher levels. Choose from 1G to 10G to suit your needs.
Location: United States, North Carolina, Durham
Employees: 51-200
Phone: +1 919-806-1074
Total raised: $45M
Founded date: 2000
Investors 4
| Date | Name | Website |
| - | Asset Mana... | assetman.c... |
| - | Aisling Ca... | aislingcap... |
| - | Canaan Par... | canaan.com |
| - | New Leaf V... | nlvpartner... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 14.02.2011 | Series F | $45M | - |
Mentions in press and media 20
| Date | Title | Description |
| 06.08.2025 | Named 'Great Place to Work,' Moon Rabbit Reports Record Growth, New Clients, Industry Accolades | Moon Rabbit Independent agency forges key industry partnerships, hires 28 new employees to fuel expansion NEW YORK, Aug. 6, 2025 /PRNewswire-PRWeb/ -- Moon Rabbit, an independent advertising and marketing agency focused on pharma and health... |
| 14.09.2022 | FDA warns monkeypox could mutate if antiviral drug is overused | The monkeypox virus is only one mutation away from evading a key antiviral drug being used to treat at-risk patients, federal health officials are now warning — and they're urging doctors to be "judicious" in prescribing the sough... |
| 22.08.2022 | Charging for expanded access drugs: FDA to let companies recoup their costs over time | The FDA on Monday updated guidance from 2016 on how companies can charge for investigational drugs under an IND, now telling sponsors working under expanded access that they can spread out their manufacturing, admini... |
| 03.05.2020 | Chimerix starts Phase II/III trial of heparin-derived blood cancer drug in Covid-19 | The latter property could be important in Covid-19, which, in addition to causing potentially fatal cytokine storms, has also been linked to embolisms and strokes, even in patients who are young and who have mild to moderate disease. Both s... |
| 06.02.2019 | Three senior Chimerix execs to hold the fort to replace departing CEO Berrey | Michelle Berrey — the woman who replaced Chimerix CEO Kenneth Moch in 2014 after the company notoriously denied a dying child compassionate use of its experimental treatment — has stepped down for undisclosed reasons, t... |
| 22.12.2014 | NYU prof: Right to try laws will not get experimental drugs to the sick people who need them | Ultimately, the family won. Chimerix initiated a clinical trial of the drug for adenovirus in immunocompromised patients, Hardy got the drug and the treatment worked. Some might point to this case as a fine example of the power of social me... |
| 25.08.2014 | Startup’s antiviral drug combats HPV, new study shows | Hera Therapeutics doesn’t yet know the exact steps the antiviral takes, but it essentially blocks the pathway that allows the virus to make its DNA using cellular enzymes, Hostetler said. “It’s a nucleoside analog, and that’s all we’re wili... |
| 24.07.2012 | Merck boosts HIV drug portfolio in two licensing deals | The therapy joins Merck’s three other drugs for HIV infection including Isentress, an antiretroviral therapy for use in combination therapy for the treatment of HIV-1 infection that generated $1.3 billion in sales last year. Isentress was a... |
| 15.02.2012 | Pharmas, medical device makers set to pitch at CED Life Science conference | A total of 16 companies are scheduled to make presentations, split evenly between pharmaceuticals and medical devices. Here’s a quick rundown of the presenting companies, all of whom are either based in North Carolina’s Research Triangle or... |
| 06.02.2012 | Transplant antiviral strong in phase 2; Chimerix plans phase 3 start this year | Chimerix says that at least 65 percent of transplant recipients faced moderate to high risk of CMV from reactivated virus from donor or recipient tissue. The disease can lead to potentially life threatening conditions such as nephritis, pne... |
Show more